医学
内科学
危险系数
细胞因子释放综合征
心房颤动
心力衰竭
心脏病学
肿瘤科
嵌合抗原受体
免疫疗法
置信区间
癌症
作者
Dae Hyun Lee,Abhishek Kumar,Turab Mohammed,Lauren C. Peres,Melissa Alsina,Christina A. Bachmeier,Brandon Blue,Jason Brayer,Sanjay Chandrasekhar,Ariel Grajales Cruz,Gabe De Avila,Hany Elmariah,Rawan Faramand,Ciara L. Freeman,Michael D. Jain,Sushmita Khadka,Farhad Khimani,Hien Liu,Taiga Nishihori,Laura B. Oswald
出处
期刊:Blood Advances
[Elsevier BV]
日期:2023-06-12
卷期号:7 (16): 4247-4257
被引量:19
标识
DOI:10.1182/bloodadvances.2023009766
摘要
Abstract Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, λ light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (≥grade 2) cytokine release syndrome (CRS) and immune cell–associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.
科研通智能强力驱动
Strongly Powered by AbleSci AI